clinical trial · NCT06793709
A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy
Eisai Co., Ltd.·—·recruiting·n = 60
Biliary Tract CancerNo Intervention
brief summary
The primary purpose of this study is to investigate the safety of Tasfygo.
started
Jul 10, 2025
primary completion
Nov 20, 2032
completion
Nov 20, 2032
last updated
Feb 27, 2026
official title
Post-marketing Observational Study of Tasfygo Tablet 35 mg to Evaluate the Safety of Tasfygo in Patients With Unresectable Biliary Tract Cancer With FGFR2 Fusion Gene Positivity Who Progressed After Chemotherapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol